← All trials
NCT06280716
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 24, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Nov 30, 2026
- First posted
- Feb 28, 2024
- Last posted
- Oct 17, 2024
- Enrollment
- 430
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.